335results about How to "Reduce pathogenicity" patented technology

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a calcium channel blocker is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites. Preferred calcium channel blockers are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a 9alpha,11alpha-substituted epoxy moiety. A preferred combination therapy includes the calcium channel blocker verapamil HCl (Benzenacetonitrile, (±)-alpha[3[[2-(3,4-dimethoxyphenyl) ethyl]methylamino]propyl]-3,4-dimethoxy-alpha-(1-methylethyl)hydrochloride) and the aldosterone receptor antagonist epoxymexrenone.

Compounds having unique antiviral properties found in mushroom mycelium and their analogs are extracted, concentrated, isolated or manufactured to create compositions useful in preventing the spread and proliferation of various viruses afflicting animals, particularly viruses harming humans, pigs, birds, bats and bees. Such compounds and compositions can be used individually or in combination with known medicines or natural products to improve health.

The invention discloses a genotype VII Newcastle disease virus marker vaccine strain and an application thereof, and belongs to the field of genotype VII Newcastle disease virus marker vaccine strain rescue and application. A built Newcastle disease virus reverse genetic operating platform is utilized for enabling NP protein of a G7 strain to miss 18 amino acids and conducting mutation on F-protein cleavage loci, and the highly-weak virulence and high-virus titer genotype VII Newcastle disease virus marker vaccine strain MG7-NPdelta18+Fmut is rescued through screening. The microbial preservation serial number is CCTCC NO: V201505. The marker vaccine strain has the biological characteristics of high growth titer and low virulence in chick embryos and is genetically stable. The immune protection test result shows that the marker vaccine strain is good in immunogenicity, capable of inducing high-level protective antibodies, and capable of completely protecting immunized chicken, can be used for preventing and controlling a currently-popular genotype VII Newcastle disease virus and lays the foundation of identifying vaccine immunity and wild virus infection.

Live, attenuated recombinant rabies virus vaccines are generated using reverse genetics to combine the antigenic determinants that render the rabies virus non-pathogenic with the determinants that are responsible for the elicitation of an effective anti-rabies immune response. These vaccines do not affect the antigenic, and therefore the immunogenic, properties of the virus. The present invention further relates to recombinant rabies virus vaccines that express a pro-apoptotic protein, such as cytochrome c, to increase the capacity to induce apoptosis, thereby enhancing the protective immunity against rabies. This new generation of live rabies virus vaccines represents a safe and effective approach to the eradication of rabies in wildlife, and subsequently humans and livestock.

The invention discloses a pathogenic related protein VdGRP1 from verticillium dahliae kleb and a coded gene thereof. The pathogenic related protein is the protein of 1) or 2): 1) the protein consisting of the amino acid sequence shown as sequence 2 in a sequence table; and 2) the protein formed by substituting and/or deleting and/or adding one or more amino acid residues of the amino acid residuesequence shown as sequence 2 in the sequence table, related to pathogenic fungi and derived from 1). A mutant strain vdgrpl of which the pathogenicity is weakened is obtained by screening a verticillium dahliae kleb mutant library mediated by agrobacterium tumefaciens and built through T-DNA insertion technology by the inventor. Southern hybridization proves that the mutant strain is a T-DNA single-insertion mutant. A gene causing mutant phenotype is obtained through TAIL-PCR technology by the inventor. Gene complementation tests prove that the mutation of the gene VdGRP1 weakens the pathogenicity of the strain vdgrpl which means that the gene VdGRP1 is a fungi pathogenic related gene.

A novel pharmaceutical composition is provided by which nonsteroidal anti-inflammatory drugs (NSAIDs) are added directly to phospholipid-containing oil such as lecithin oils or to a bio-compatible oil to which an phospholipid has been added to make a NSAID-containing formulation that possess low gastrointestinal (GI) toxicity and enhanced therapeutic activity to treat or prevent inflammation, pain, fever, platelet aggregation, tissue ulcerations and/or other tissue disorders. The composition of the invention are in the form of a non-aqueous solution, paste, suspension, dispersion, colloidal suspension or in the form of an aqueous emulsion or microemulsion for internal, oral, direct or topical administration.

The present invention provides purified protease inhibitors derived from microorganisms alone or in combination with bacteriocins and/or antibodies. The protease inhibitors may also be expressed by microbiome or probiotic microorganisms alone or in combination with bacteriocins and/or antibodies. The invention also provides methods and compositions for improving the expression of endogenous or heterologous protease inhibitors alone or in combination with bacteriocins and/or antibodies. The invention is useful for treating a variety of inflammatory disorders including acne, psoriasis, eczema, atopic dermatitis and inflammatory bowel disease.

The invention provides building and application of an M protein three-amino acid site-mutated vesicular stomatitis virus (VSV) carrier for pigs. The VSV carrier is matrix protein (M) three-amino acid site-mutated recombinant virus VSV-MT, the 51st-site methionine of the virus M protein is knocked out, the 221st-site valine of the virus M protein is mutated into phenylalanine, and the 226th-site glycine of the virus M protein is mutated into arginine. The VSV carrier is extremely low in pathogenicity, high in safety, capable of effectively stimulate a body to produce protective immune response, applicable to vaccine or vaccine carrier preparation, and promising in application prospect.

The invention relates to a Newcastle disease chimeric virus marker vaccine strain as well as a construction method and application thereof, and belongs to the field of rescue and application of Newcastle disease chimeric vaccine strains. A Newcastle disease virus reverse genetic operation platform is utilized to mutate an F protein cleavage site of a Newcastle disease gene GVII type strain into acleavage site of an attenuated strain, F and HN genes of a mutated gene VII type Newcastle disease strain and NP, P, M and L of a gene II type NDV La Sota strain construct a full-length chimeric cDNAsequence, and a 18bp nucleotide marker sequence is inserted into a non-coding region between P and M. A Newcastle disease chimeric virus NDV DC strain is obtained through transfection cell rescue. Theconstructed chimeric virus can reach relatively high culture titer in chick embryos and cells. The chimeric strain contains envelope surface glycoprotein of the gene VII type Newcastle disease strain, contains a skeleton of the gene II type strain, and has immunogenicity of the Newcastle disease gene VII type strain and high reproduction and high safety characteristics of the gene II type La Sotastrain.

The present invention discloses a method for attaining potato plates which are disease resistant by utilizing agrobacterium-mediated hrap gene. After the combined inoculation of the method and the bacteria allergic protein harpinPss, the allergic reaction caused by harpinPss can be promoted in the intercellular space of all inoculated plates, and the polymeride of harpinPss is dissociated, so the disease resisting effect is better, and the disease resistance of the potato plates can be promoted. The hrap gene is introduced in the potato plates through the agrobacterium-mediated, thus resulting that the potato plates have the ability to resist the late blight and the bacterial wilt. The present invention has the technical proposal that the pre-cultured explants are inoculated in the agrobacterium germ liquid to be soaked, explants after being soaked select the tube seedling which can root after two times of root selections by co-culturing, callus of induce, bud inducting and rootage cultivating and selecting, and the potted transformed plants are transferred after the mass propagation, the transformed plants select positive plants by the methods of the PCR detection and the Southern hybridization detection, and then the potato plates which are disease resistant can be obtained by the in-vivo inoculation resistance identification. The present invention improves the callus of inducing and the bud inducing of the explants, and enhances the agrobacterium-mediated ability. That the roots of the explants are selected by two times can eliminate the false positive plates in the transformation process , avoid the continuing cultivation to the false positive plates, save the labour force and decrease the manufacturing cost.

The present invention provides cell fusogenic vectors having replicative ability, whose protease-dependent tropism has been modified. M gene-deficient viral vectors encoding modified F proteins, in which the cleavage site of the F protein of paramyxovirus is modified to be cleaved by different proteases, were produced. In cells transfected with these vectors, the genomic RNA present in the vectors is replicated, and cell fusogenic infection spreads to neighboring cells depending on the presence of other proteases; however, no viral particles are released. The vectors of this invention, encoding the F proteins which are cleaved by proteases whose activity is enhanced in cancer, show cancer growth suppressive effect in vivo.

The present invention is a culture of cells of Haemophilus parasuis exhibiting attenuated pathogenicity and capable of triggering a protective immune response when administered to pigs as a live vaccine. The present invention is also a method of preparing the cell culture, a method of preparing a vaccine from the cell culture, and a live vaccine based on the cell culture. The cell culture was modified from a pathogenic parent strain by MNNG mutagenesis and was selected by complete dependence on streptomycin for growth.

The invention relates to a recombination newcastle disease LaSota attenuated vaccine for expressing canine distemper virus fusion protein (F) or canine distemper virus hemagglutinin protein (H). Particularly, the recombination newcastle disease LaSota attenuated vaccine is rLa-CDVR-F or rLa-CDVR-H. The invention further discloses a method for preparing the recombination newcastle disease LaSota attenuated vaccine and application of the recombination newcastle disease LaSota attenuated vaccine in preparation of vaccines/kits.

The invention discloses a method for constructing genetic engineering strains for producing (R)-acetoin and application of the genetic engineering strains. The method includes optimizing codons of nucleotide sequences of alpha-acetolactate synthase genes, alpha-acetolactate decarboxylase genes and NADH (reduced form of nicotinamide adenine dinucleotide) oxidase genes and acquiring each gene cluster with three genes by the aid of artificial synthesis processes; inserting the gene clusters into expression vectors to obtain polycistron recombinant plasmids; introducing the polycistron recombinant plasmids into host bacteria E. coli and knocking out key genes of main byproduct synthesis paths to obtain the genetic engineering strains for producing the (R)-acetoin. The method and the application have the advantages that raw materials for the genetic engineering strains can come from wide sources and are low in cost, the strains are free of pathogenicity, oxidized form coenzymes NAD+ (nicotinamide adenine dinucleotide+) can be effectively regenerated, the strains are high in (R)-acetoin yield and production efficiency, the maximum yield can reach 72.1 g/L, and the optical purity can reach 99% at least; the (R)-acetoin is produced by the aid of non-grain cassava flour and inexpensive nitrogen sources which are used as fermentation raw materials, and accordingly the production cost can be reduced.